InterMune Announces Clinical Data: Infergen(R) and Ribavirin

From Hepatitis C Resource Centre

November 14, 2005

InterMune Announces Clinical Data Presented at AASLD That Support Phase III DIRECT Trial for HCV: Early data suggests that daily 15 microgram dosing of Infergen(R) in combination with ribavirin may be a viable treatment option for pegylated interferon plus ribavirin non-responders and relapsers, and encouraged further study. more